Safety and Tolerability of Mebendazole in Infants Under 1 Year of Age

Yaara Kahan; Eve Lugassy-Akian; Adi Ovadia; Ilan Dalal; Eli Somekh; Diana Tasher

doi:10.1093/jpids/piab077

Safety and Tolerability of Mebendazole in Infants Under 1 Year of Age

J Pediatric Infect Dis Soc. 2021 Sep 1:piab077. doi: 10.1093/jpids/piab077. Online ahead of print.

Authors

Yaara Kahan^{1

2}, Eve Lugassy-Akian^{2

3}, Adi Ovadia^{2

3}, Ilan Dalal^{2

3}, Eli Somekh^{2

4}, Diana Tasher^{1

2}

Affiliations

¹ Pediatric Infectious Diseases Unit, Edith Wolfson Medical Center, Holon, Israel.
² Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
³ Department of Pediatrics, Edith Wolfson Medical Center, Holon, Israel.
⁴ Department of Pediatrics, Mayanei HaYeshua Medical Center, Bnei-Brak, Israel.

PMID: 34468731
DOI: 10.1093/jpids/piab077

Abstract

This paper presents the largest cohort to date of infants under 1 year of age treated with mebendazole. We evaluated the occurrence of mebendazole-associated clinical and laboratory toxicity as safety data in this age group are currently lacking.

Keywords: adverse events; infants; mebendazole; safety; under 1 year.

© The Author(s) 2021. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.